Genmab

	1/12 15:09 af Bulder	”De bispecifikke antistoffer repræsenterer en ny immunterapi-æra. I lymfomer ser det rigtig lovende ud, og inden for myelomatose ser vi også gode takter. Det er et princip, jeg har stor tiltro til. Og som jeg forudser kommer til at udkonkurrere CAR-T i en række hæmatologiske sygdomme på sigt,” siger Torben Plesner. (link)
	1/12 10:29 af AaBforever	Så må vi jo se om den kommer derop;-)
	1/12 09:35 af Vitus	Det synes jeg også du skal.......
	1/12 09:10 af StockBull	Tror jeg sælger min spekulative portion i 2500-2600 områden inden weekenden (link)
	1/12 09:03 af StockBull	God morgen :-)
	1/12 07:50 af bibob	God morgen. :-)
	1/12 07:39 af Helge Larsen/PI-redaktør	Tirsdagens aviser med Mærsk, Vestas og Ringkjøbing Landbobank(link)
	1/12 07:38 af Helge Larsen/PI-redaktør	Asien: Investorerne tager hul på julemånedens gaveregn: (link)
	1/12 07:31 af Helge Larsen/PI-redaktør	God morgen. :-)
	1/12 06:15 af Klarussen	Godmorgen. NBI +1,09%, endnu en dag for defensive aktier venter. Spændende om vi holder slutkursen fra i går.
	30/11 23:17 af peter12	Gen's Curevac aktiepost har steget til det dobbelte siden regnskabet (>1.3mia dkr). Curevac lukkede >20% oppe
	30/11 22:50 af Sukkeralf	(link)
	30/11 19:36 af Klarussen	Købte en pæn slat i 2185 og har ikke set mig tilbage siden :-) Har bestemt ikke noget imod at være i selskab med the grand old man hvis det skulle være tilfældet.
	30/11 19:17 af Klarussen	Mon ikke det er Buffet som smider nogle håndører i Genmab? ;-)
	30/11 19:12 af Klarussen	Lover godt fremover, he he...
	30/11 18:34 af Legolas23	Heller ikke jeg..
	30/11 18:08 af Bulder	de 35 kr reddede da lige dagen. Mindes ikke at have set noget lignende før.
	30/11 18:06 af E L	actually, let me correct that, ANY selling is a bear trap :-D
	30/11 18:06 af E L	in hindsight that selling on enapotamab news was a huge bear trap
	30/11 18:01 af Rondo	WOOOO!!!!!
	30/11 18:01 af BioShare	Herligt luk i 2.394 :-)
	30/11 18:01 af E L	somebody was slightly underweight for month end lol
	30/11 18:00 af E L	wtf....
	30/11 17:56 af JørgenVarnæs	Nyheder? Heftig lukkeauktion

	30/11 16:42 af E L	HexaBody video (link)
	30/11 16:34 af E L	last day of the month. Highest monthly close so far was 2356 in august, let's see if we can beat that
	30/11 11:30 af StockBull	Nyt købssignal via SAXO som taler for sig selv. P.t ser det mega positivt ud om mon ikke der suppleres op til ASH den 8 December (link)
	30/11 09:25 af transalp	Go morgen.. :)
	30/11 07:44 af Helge Larsen/PI-redaktør	Mandagens aviser: (link)
	30/11 07:43 af Helge Larsen/PI-redaktør	God morgen. :-)
	30/11 06:04 af Sukkeralf	(link)
	29/11 21:06 af Klarussen	God aften og god 1. søndag i advent. Mon ikke vi kører videre opad i morgen. NBI var frisk i fredags, også andre defensive aktier i DK (GN f.eks.) tog et spring op igen. Skal vi satse på en snarlig test af kurs 2500 Stockbull? Inden jul?
	29/11 08:33 af bibob	God morgen :-)
	29/11 08:17 af Helge Larsen/PI-redaktør	God morgen, ;-)
	28/11 18:48 af Solsen	Hexacd38 has a huge potential and far byond dara. DLBCL and solid just to mention some indications. But do it work and what about SAE. And as EL point out the patent life.
	28/11 17:42 af peter12	Thx EL. Jan previously told that Janssen could decide to opt in after 10 pts treated with Hexacd38, so its interesting to follow ;-)
	28/11 13:54 af E L	the antibody targets for that one are undisclosed for now, even though Sukkeralf had a guess here on those, you should be able to search back for that, i forget ;)
	28/11 13:51 af E L	Note that JNJ-70218902 is also recently new directed at prostate cancer (link)
	28/11 13:50 af E L	I think Jan would have directed Sujit k, to JNJ for all his questions...
	28/11 13:49 af E L	ImmunoPrecise was mentioned in a question but not really answered...
	28/11 13:47 af E L	I have seen articles therefore stating that market could be quit a bit larger. JNJ also indicated this at some point and said would put efforts into doctors education
	28/11 13:47 af E L	many patients are never propperly diagnosed as having it
	28/11 13:47 af E L	as the symptons do not always easily point to amyloidosis,
	28/11 13:46 af E L	Btw on amyloidosis, some say the disease size is seriously underestimated;
	28/11 13:42 af E L	possibly for later lines, or, as they have inidicated, in combo with cd38
	28/11 13:39 af GeorgeBest	Thanks E L, also my thoughts. Will keep Sarclisa and CarT on the backfoot. But on the other hand JNJ already have CarT through Legend!
	28/11 13:38 af E L	btw GB; you asked on amyloidosis; even though the market is much smaller, I would hope for a much faster uptake and immediately into first line as it really seems to be such a good drug for this disease
	28/11 13:28 af E L	On GB / Hexacd38; 1. competition does not stop working and Dara may not remain the best cd38 forever. 2. Dara patent will roll off at some point; hexa would give a new patentlife to the the cd38 business 3. hexa could sigfnificantly enlarge their cd38 business if it works in other disease areas (and Jan has several times hinted that that could be the case)
	28/11 13:19 af E L	My guess for the moment is that we will at least see something utilizing AbbVie’s ADC technology, which Jan recently called ADC 3.0. My gutfeel is that he thinks it is better as ADCT's technology or even Seagen's and that it could be one of the reasons CamiT is not further persued. purely guessing offcourse.
	28/11 13:15 af E L	pretty certain that that is a typo and should be a NO @peter.